Comparison of the dosimetry of scandium-43 and scandium-44 patient organ doses in relation to commonly used gallium-68 for imaging neuroendocrine tumours.

BACKGROUND: Several research groups have explored the potential of scandium radionuclides for theragnostic applications due to their longer half-lives and equal or similar coordination chemistry between their diagnostic and therapeutic counterparts, as well as lutetium-177 and terbium-161, respectively. Unlike the gallium-68/lutetium-177 pair, which may show different in-vivo uptake patterns, the use of scandium radioisotopes promises consistent behaviour between diagnostic and therapeutic radiopeptides. An advantage of scandium's longer half-life over gallium-68 is the ability to study radiopeptide uptake over extended periods and its suitability for centralized production and distribution. However, concerns arise from scandium-44's decay characteristics and scandium-43's high production costs. This study aimed to evaluate the dosimetric implications of using scandium radioisotopes with somatostatin analogues against gallium-68 for PET imaging of neuroendocrine tumours. METHODS: Absorbed dose per injected activity (AD/IA) from the generated time-integrated activity curve (TIAC) were estimated using the radiopeptides [43/44/44mSc]Sc- and [68Ga]Ga-DOTATATE. The kidneys, liver, spleen, and red bone marrow (RBM) were selected for dose estimation studies. The EGSnrc and MCNP6.1 Monte Carlo (MC) codes were used with female (AF) and male (AM) ICRP phantoms. The results were compared to Olinda/EXM software, and the effective dose concentrations assessed, varying composition between the scandium radioisotopes. RESULTS: Our findings showed good agreement between the MC codes, with - 3 ± 8% mean difference. Kidneys, liver, and spleen showed differences between the MC codes (min and max) in a range of - 4% to 8%. This was observed for both phantoms for all radiopeptides used in the study. Compared to Olinda/EXM the largest observed difference was for the RBM, of 21% for the AF and 16% for the AM for scandium- and gallium-based radiopeptides. Despite the differences, our findings showed a higher absorbed dose on [43/44Sc]Sc-DOTATATE compared to its 68Ga-based counterpart. CONCLUSION: This study found that [43/44Sc]Sc-DOTATATE delivers a higher absorbed dose to organs at risk compared to [68Ga]Ga-DOTATATE, assuming equal distribution. This is due to the longer half-life of scandium radioisotopes compared to gallium-68. However, calculated doses are within acceptable ranges, making scandium radioisotopes a feasible replacement for gallium-68 in PET imaging, potentially offering enhanced diagnostic potential with later timepoint imaging.

Proposed DRLs for mammography in Switzerland.

The aim of this study is to propose diagnostic reference levels (DRLs) values for mammography in Switzerland. For the data collection, a survey was conducted among a sufficient number of centres, including five University hospitals, several cantonal hospitals, and large private clinics, covering all linguistic regions of Switzerland to be representative of the clinical practice. The data gathered contained the mean glandular dose (MGD), the compressed breast thickness (CBT), the mammography model and the examination parameters for each acquisition. The data collected was sorted into the following categories: 2D or digital breast tomosynthesis (DBT) examination, craniocaudal (CC) or mediolateral oblique (MLO) projection, and eight categories of CBT ranging from 20 mm to 100 mm in 10 mm intervals. A total of 24 762 acquisitions were gathered in 31 centres on 36 mammography units from six manufacturers. The analysis showed that the data reflects the practice in Switzerland. The results revealed that the MGD is larger for DBT than for 2D acquisitions for the same CBT. From 20-30 mm to 90-100 mm of CBT, the 75th percentile of the MGD values obtained increased from 0.81 mGy to 2.55 mGy for 2D CC acquisitions, from 0.83 mGy to 2.96 mGy for 2D MLO acquisitions, from 1.22 mGy to 3.66 mGy for DBT CC acquisitions and from 1.33 mGy to 4.04 mGy for DBT MLO acquisitions. The results of the survey allow us to propose Swiss DRLs for mammography according to the examination type (2D/DBT), projection (CC/MLO) and CBT. The proposed values are very satisfactory in comparison with other studies.

Effects of convolution filter with beam hardening correction on computed tomography image quality.

PURPOSE: To quantify the effects of convolution filters (FC) with beam hardening correction (BHC) compared to FC without BHC on the computed tomography (CT) image quality. METHODS: This study was conducted on a Canon® Aquilion Lightning scanner. The exposure protocol includes acquisitions at 120 and 100 kVp. Sixteen FCs (8 with and 8 without BHC) were investigated using a Catphan®504 phantom. Uniformity, slice thickness, spatial resolution, Hounsfield unit and noise were analysed using the SPICE-CT ImageJ plugin and the noise power spectrum was analysed using the Imquest software. RESULTS: It was observed that the BHC did not significantly influence the uniformity, slice thickness, noise and noise power spectrum. Comparisons of 10% MTF between FC01 and FC11 showed relative differences of -29% and -5% at 120 and 100 kVp, respectively, while those between FC09 and FC19 were -55% and -25%. The Hounsfield unit of the Catphan's region of highest electron density was reduced by -7.29% at 120 kVp for FC with BHC. In both cases (FC with and without BHC), the noise values agreed with CT operating manual. At 120 kVp, FC11 and FC09 presented the maximum and minimum noise values, respectively. CONCLUSION: In CT procedures that quantitatively evaluate the bone or calcium Hounsfield unit, FC with BHC should be avoided due to its effects on Hounsfield units, in special at higher voltage, such as 120 kVp.

Optimising whole body computed tomography doses for paediatric trauma patients: a Swiss retrospective analysis.

We aimed to evaluate the impact of a low-dose whole-body computed tomography (WBCT) protocol on radiation doses in paediatric major trauma patients. Retrospective cohort study of paediatric trauma patients (<16 years) at a national level 1 paediatric trauma centre (PTC) over a 6 year period prior and post introduction of a low-dose WBCT protocol (2014-2019). Demographic data, patient characteristics, CT device, and exposure information including scan range, dose-length product, and volume CT dose index were collected. Effective dose (ED) and exposure parameters were compared before and after protocol introduction. Forty-eight patients underwent WBCT during the study period. Prior to introduction of the low-dose protocol (n= 18), the ED was 20.6 mSv (median 20.1 ± 5.3 mSv [range 12.5-30.7]). After introduction of the low-dose WBCT protocol (n= 30), mean ED was 4.8 mSv (median 2.6 ± 5.0 [range: 0.8-19.1]). This resulted in a reduction of 77% in mean ED (pvalue <0.001). Significant radiation dose reduction of 77% can be achieved with low-dose WBCT protocols in PTCs.

New Radionuclides and Technological Advances in SPECT and PET Scanners.

Developments throughout the history of nuclear medicine have involved improvements in both instrumentation and radionuclides, which have been intertwined. Instrumentation developments always occurred during the search to improving devices' sensitivity and included advances in detector technology (with the introduction of cadmium zinc telluride and digital Positron Emission Tomography-PET-devices with silicon photomultipliers), design (total body PET) and configuration (ring-shaped, Single-Photon Emission Computed Tomography (SPECT), Compton camera). In the field of radionuclide development, we observed the continual changing of clinically used radionuclides, which is sometimes influenced by instrumentation technology but also driven by availability, patient safety and clinical questions. Some areas, such as tumour imaging, have faced challenges when changing radionuclides based on availability, when this produced undesirable clinical findings with the introduction of unclear focal uptakes and unspecific uptakes. On the other end of spectrum, further developments of PET technology have seen a resurgence in its use in nuclear cardiology, with rubidium-82 from strontium-82/rubidium-82 generators being the radionuclide of choice, moving away from SPECT nuclides thallium-201 and technetium-99m. These continuing improvements in both instrumentation and radionuclide development have helped the growth of nuclear medicine and its importance in the ever-evolving range of patient care options.